載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.7599
−US$0.014 · -1.81%
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
前收盤價
US$0.7599
−US$0.014 · -1.81%
盤中時間採用ET。市場資料可能有所延遲。
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
日內區間
目前US$0.7599
52週區間
目前US$0.7599
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
50
合理估值
情緒
57
多空交錯
風險
69
高風險
動能
24
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
日內區間
目前US$0.7599
52週區間
目前US$0.7599
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 2.71萬 USD | 2.79萬 USD | 2.5萬 USD | 4萬 USD | — |
| 毛利 | −2.71萬 USD | −2.79萬 USD | −2.5萬 USD | −4萬 USD | — |
| 研究與開發 | 406.39萬 USD | 354.9萬 USD | 414.59萬 USD | 537.74萬 USD | 691.48萬 USD |
| 銷售、一般及管理費用 | 500.7萬 USD | 442.61萬 USD | 451.08萬 USD | 548.71萬 USD | 503.57萬 USD |
| 營業費用 | 907.08萬 USD | 797.51萬 USD | 865.67萬 USD | 1086.45萬 USD | 1195.05萬 USD |
| 利息支出 | — | — | — | — | 4.18萬 USD |
| 折舊和攤銷 | 2.71萬 USD | 2.79萬 USD | 2.5萬 USD | 2.5萬 USD | 1.68萬 USD |
| 營業利益 | −907.08萬 USD | −797.51萬 USD | −865.67萬 USD | −1086.45萬 USD | −1195.05萬 USD |
| 淨利 | −891.36萬 USD | −1503.85萬 USD | −12.03萬 USD | −1082.95萬 USD | −1198.68萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年1月28日 | 1:4 | — | — |
股票分割 | 2025年7月7日 | 1:3 | — | — |
股票分割 | 2025年1月28日 | 1:16 | — | — |
股票分割 | 2024年1月25日 | 1:30 | — | — |
股票分割 | 2023年2月1日 | 1:35 | — | — |
已生效 2026年1月28日
1:4
已生效 2025年7月7日
1:3
已生效 2025年1月28日
1:16
已生效 2024年1月25日
1:30
已生效 2023年2月1日
1:35
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
